A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study.
about
Maintenance treatment with antipsychotic drugs for schizophreniaAtypicality of atypical antipsychotics.Schizophrenia relapse, patient considerations, and potential role of lurasidoneZiprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsThe effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.Ziprasidone hydrocloride: what role in the management of schizophrenia?Weight gain, obesity, and psychotropic prescribing.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.Optimizing dosing in atypical neuroleptic monotherapyHigh relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China.Psychiatric medication-induced obesity: a review.Quantifying clinical relevance in the treatment of schizophrenia.A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.Symptom domains of schizophrenia: the role of atypical antipsychotic agents.Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.Treatment of psychosis: 30 years of progress.Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders.Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study.Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot studyDropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design featuresDose equivalents for second-generation antipsychotics: the minimum effective dose method.Drug safety evaluation of ziprasidone.Adverse Drug Events Related to Ziprasidone: A Meta-analysis of Randomized, Placebo-Controlled Trials.Obesity and psychotropics.Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder.Pharmacological treatment of negative symptoms in schizophrenia.The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.Commentary: consensus statement on negative symptoms.Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval.Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.
P2860
Q24197902-E8512C86-0652-4A33-B4FE-792EF4FC152BQ24535908-33114FA4-322D-4501-B1AE-092119602812Q26738850-0D26BCF9-5149-4772-B434-6CCE3144F845Q30984472-56239001-92C0-4C0B-8582-0719D0DFA415Q33223628-18BB4E16-BB82-498B-B7F8-6074981C1B68Q33235110-3DDCC9A9-EEC3-485F-8B4A-D8E8D3D933AAQ33566124-CC3CB600-5DF7-4A47-A262-36E2E1838665Q33619940-D7AA93EC-F2E6-436E-96F3-580E71C56C86Q33814003-69942637-2E9D-4EA8-9A3E-5CC4F43983A4Q34106516-12246968-CA0C-4D72-91F4-C09DCE4E3DCBQ34357931-1A42186C-2866-4892-A907-CF487476341EQ34557537-58D8969F-BFC9-4430-A928-1120025D3774Q34640811-563597AD-2EB0-494B-91C6-CE0DCC86714FQ34733976-D06271D2-237A-4E84-B16C-0A3B7EA98317Q35065378-BDC19B4B-22FF-4A81-A1FD-DD337AA13015Q35236514-34CDDE65-6F5E-4982-972A-A7200174B6B1Q35605892-24C520D4-79DA-4093-B396-4D6949261870Q35746806-B592C8B7-1A53-4857-8966-8EBE8027D414Q35819467-2B8796A8-3800-46DE-8A88-261C5B036529Q36475355-09D9ADC7-D7CE-4995-887C-A6D29C6BD89AQ36626242-F9AED17B-F74B-49B4-BD3C-DC22AB109313Q36626247-B1E01E47-2BA3-40F5-997A-178005655C76Q36687060-61078040-C289-4532-A572-A846344FF807Q36700337-E1CB0C33-92E3-495C-9CB5-00799515FDF3Q36715888-62987D55-11EE-4410-B92B-D910FB044F6FQ36908237-70EE2927-12D1-487E-A498-05978F98EB02Q37060012-EB4C40E2-065D-4788-AB77-3700072BDB70Q37227479-F8832D82-FBBA-4628-9CEB-CAA7AFF15099Q37598284-C6C82B86-AC46-455E-A98B-2B596B43E64FQ37844574-3E8E8D1F-E5D9-4163-AB86-CEB8E7FC9E21Q37933405-7A80D308-1FE6-4C34-9D4F-352CAA576262Q37954390-471714C9-E968-4262-9546-4C3D54E677AFQ38032249-CFC42CEC-1103-4780-A4C9-DB22775E7D16Q38284625-1FF92BE9-D6E6-4C74-9B95-7B918C3186A4Q38431333-2A14B900-67C1-4597-82E5-87497A336F9BQ38570636-5D7BDBD0-F88C-4851-9E7F-C66CBC0A8E78Q38838664-E4570775-0CEC-4BD7-8F1D-F308EF610299Q41931708-557364F3-B37B-4FD1-B44C-D1DD14E8A10CQ42610530-7214E151-A5B1-4FC4-9BD7-07BFBB9B951DQ43227531-54213F18-A730-4865-87D1-DF888D9E2751
P2860
A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
A 1-year, double-blind, placeb ...... in Schizophrenia (ZEUS) study.
@en
A 1-year, double-blind, placeb ...... in Schizophrenia (ZEUS) study.
@nl
type
label
A 1-year, double-blind, placeb ...... in Schizophrenia (ZEUS) study.
@en
A 1-year, double-blind, placeb ...... in Schizophrenia (ZEUS) study.
@nl
prefLabel
A 1-year, double-blind, placeb ...... in Schizophrenia (ZEUS) study.
@en
A 1-year, double-blind, placeb ...... in Schizophrenia (ZEUS) study.
@nl
P2093
P1476
A 1-year, double-blind, placeb ...... in Schizophrenia (ZEUS) study.
@en
P2093
H Y Meltzer
R O'Connor
ZEUS Study Group
P304
P356
10.1097/00004850-200209000-00001
P577
2002-09-01T00:00:00Z